Lymphocytic Vasculitis of the Uterus in a Patient With Melanoma Receiving Ipilimumab
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Case Report A 77-year-old woman developed in-transit and lymphatic metastases from melanoma after multiple previous therapies. She received four dosesof ipilimumab3mg/kgbeginninginSeptember2011.Fifteenweeks after starting treatment, she developed hypophysitis with low levels of cortisol and thyroid-stimulating hormone; her symptoms responded to appropriate hormonal replacement. Positron emission tomography (PET)/computed tomography scan in May 2012 documented complete remission of her melanoma. She received additional doses of ipilimumab 3 mg/kg in March and June 2012 without apparent adverse effects. A routine PET/computed tomography scan in August 2012 appeared to show a 4.8-cm mass in the uterus (SUV 9.2) with bilateral iliac lymphadenopathy (Fig 1). She had no pelvic pain, bleeding, or previous gynecological disease. Because of suspicion of recurrent malignancy she had a hysterectomy in September 2012. Pathology showed lymphocytic vasculitis involving uterine and ovarian vessels (Fig 2), with transmural infiltration of lymphocytes and focal fibrin deposition. The iliac lymph nodes thatwereremovedshowedonlyreactivechanges.Serologic studies subsequently showed normal antinuclear antibodies but a high titer of antithyroglobulin antibody—3,591 IU/mL (normal, 0-40 IU/mL).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Cited by
Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
Cappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2017) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 403
Hassel, J. C., Heinzerling, L., Aberle, J., Bähr, O., Eigentler, T. K., Grimm, M.-O., Grünwald, V., Leipe, J., Reinmuth, N., Tietze, J. K., et al. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.003 · Cited by 331
Vasculitis associated with immune checkpoint inhibitors—a systematic review
Daxini, A., Cronin, K., & Sreih, A. G. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4177-0 · Cited by 266
Kwak, J. J., Tirumani, S. H., Van den Abbeele, A. D., Koo, P. J., & Jacene, H. A. (2015) · RadioGraphics · doi:10.1148/rg.352140121 · Cited by 167
Metadata
- Authors
- Minor, D. R., Bunker, S. R., & Doyle, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-07-10
- Volume
- 31
- Issue
- 20
- Pages
- e356-e356
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2171580322
- Cited by
- 37
- References
- 1
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.